Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

and pharmacokinetics of tezampanel

given once-daily for four consecutive days. Data from this multiple

dose trial are intended to support the continued development of

tezampanel for the treatment of migraine, as well as allow TorreyPines

to consider expanding the development of tezampanel into additional

chronic pain conditions.

-- Completed a Phase I multiple-dose clinical trial of NGX267 in

development for cognitive impairment associated with schizophrenia

(CIAS). NGX267 was found to be safe and well-tolerated. The clinical

trial also demonstrated that NGX267 increases salivary flow, which may

be beneficial in treating xerostomia, or dry mouth.

-- Extended the genetics discovery collaboration with Eisai Co., Ltd.

This agreement focuses on the discovery of Alzheimer's disease targets

using whole-genome family-based association screening. Under terms of

the agreement, TorreyPines received an upfront payment and continued

research funding in support of the program for an additional year.

Financial Results

Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.

Revenue for the nine month period ended September 30, 2007 was $7.4 million compared to revenue of $7.4 million for the same period in 2006. Operating expenses for the nine month period were $24.6 million, with $20.4 million attributabl
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014 Bina Technologies, ... USA) announced today that they have been acquired by ... is a privately held company that provides a ... next generation sequencing (NGS) data for the academic and ... Roche Sequencing Unit, and will continue to focus on ...
(Date:12/19/2014)... FL (PRWEB) December 18, 2014 ... the nation’s leading specialty pharmacies, has an expanded ... as clinical pharmacy consultants for prescriber offices in ... expertise. , “We have a variety of ... For example, those specializing in hepatitis C help ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... Feb. 14, 2012 Avaxia Biologics, Inc., a ... act locally within the gastrointestinal tract, announced today ... A angel-led financing.  Cherrystone Angels of Providence, Rhode ... Angels, Boston Harbor Angels, Launchpad Venture Group, Mass ...
... 13, 2012  Ten years ago today, a task force ... together to develop a strategy for Indiana,s life sciences ... life sciences companies and research institutions into a 21st-century ... BioCrossroads, that strategy has driven the state into the ...
... 13, 2012 Amgen (NASDAQ: AMGN ) will present ... Eastern Standard Time  on Thursday, Feb. 16, 2012, at the ... executive vice president and chief financial officer at Amgen, will ... be accessed from the Events Calendar on Amgen,s website, ...
Cached Biology Technology:Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 3BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector 2BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector 3
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Researchers at North Carolina State University have developed ... with biological systems including the human body. Their ... environmental safety in the handling of nanomaterials, as well ... Dr. Jim Riviere, Burroughs Wellcome Distinguished Professor of ...
... Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh//20050509/BIOKEYLOGO ) , ... BIO-key International, Inc. Second Quarter 2010 Conference Call , ... - 10:00 a.m. Eastern Time , ... asking for the BIO-key call at least 10 minutes prior to the ...
... the following schedule and contact information for a teleconference on financial results through the second quarter ... Monday, August 16, 2010 , ... Vice President, Investor Relations , ... London: 0800-279-9630 , Netherlands: ...
Cached Biology News:Probing the nanoparticle: Predicting how nanoparticles will react in the human body 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3Teleconference Alert: LyondellBasell Reviews Second Quarter 2010 Financial Results 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... 'Agilents GeneSpring Workgroup solution is ... managing and mining expression data in ... and is deployed in over 40 ... research organizations worldwide. GeneSpring Workgroup streamlines ...
... Western blotting is a commonly used ... Typically, protein samples are electrophoresed on SDS-PAGE ... nitrocellulose or nylon, where they are probed ... technologies, which allow reuse of Southern and ...
... for quantitative assays using recombinant proteins/antibodies ... the flexible and powerful Paraflo microfluidic ... sequences can be synthesized on-chip and ... custom sequence design. These microarrays are ...
Biology Products: